CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.Lorlatinib (Lorbrena, Pfizer) also drastically delayed disease progression and development of brain metastases compared with crizotinib (Xalkori, Pfizer).
CHICAGO — Adjuvant dabrafenib plus trametinib reduced mortality risk for adults with resected stage III BRAF V600-mutant melanoma, according to final results of the randomized phase 3 COMBI-AD trial. The findings, presented at ASCO Annual Meeting, also reaffirmed 3- and 5-year updates on improved RFS and distant metastasis-free survival for individuals in the study’s treatment arm.
CHICAGO — ASCO and American Cancer Society will collaborate to make it easier for patients and their caregivers to find credible cancer information online.The effort is intended to establish one of the largest, most comprehensive online sources of authoritative cancer information.
CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed. However, findings presented at ASCO Annual Meeting suggest that individuals with elevated lactate dehydrogenase or liver metastases may benefit from the treatment regimen.
Age-related changes to the skin’s elasticity may drive higher rates of metastatic skin cancer among older individuals, according to study results.Increased stiffness in aging skin leads to elevated production of a protein called ICAM1.